Diagnosis, antiviral therapy, and prophylaxis of varicella-zoster virus infections

  • A. SauerbreiEmail author


Varicella-zoster virus (VZV), an important member of the Herpesviridae family, is the etiological agent of varicella as primary infection and zoster as recurrence. An outstanding feature is the lifelong viral latency in dorsal root and cranial nerve ganglia. Both varicella and zoster are worldwide widespread diseases that may be associated with significant complications. However, there is a broad spectrum of laboratory methods to diagnose VZV infections. In contrast to many other viral infections, antiviral treatment of VZV infections and their prevention by vaccination or passive immunoprophylaxis are well established in medical practice. The present manuscript provides an overview about the basic knowledge of VZV infections, their laboratory diagnosis, antiviral therapy, and the prevention procedures, especially in Germany.


Acyclovir Thymidine Kinase Foscarnet Famciclovir Valaciclovir 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Compliance with ethical standards

Conflict of interest

The author reports no conflicts of interest.


  1. 1.
    Davison A, Eberle R, Hayward GS, McGeoch DJ, Minson AC, Pellett PE et al (2005) Herpesviridae. In: Fauquet CM, Mayo MA, Maniloff J, Desselberger U, Ball LA (eds) Virus taxonomy. Eighth Report of the International Committee on Taxonomy of Viruses. Academic Press, San Diego, pp 193–212Google Scholar
  2. 2.
    Breuer J, Grose C, Norberg P, Tipples G, Schmid DS (2010) A proposal for a common nomenclature for viral clades that form the species varicella-zoster virus: summary of VZV Nomenclature Meeting 2008, Barts and the London School of Medicine and Dentistry, 24–25 July 2008. J Gen Virol 91:821–828CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Lokeshwar MR, Agrawal A, Subbarao SD, Chakraborty MS, Ram Prasad AV, Weil J et al (2000) Age related seroprevalence of antibodies to varicella in India. Indian Pediatr 37:714–719PubMedGoogle Scholar
  4. 4.
    Wutzler P, Färber I, Wagenpfeil S, Bisanz H, Tischer A (2001) Seroprevalence of varicella-zoster virus in the German population. Vaccine 20:121–124CrossRefPubMedGoogle Scholar
  5. 5.
    Schmidt-Chanasit J, Sauerbrei A (2011) Evolution and world-wide distribution of varicella-zoster virus clades. Infect Genet Evol 11:1–10CrossRefPubMedGoogle Scholar
  6. 6.
    Hillebrand K, Bricout H, Schulze-Rath R, Schink T, Garbe E (2015) Incidence of herpes zoster and its complications in Germany, 2005–2009. J Infect 70:178–186CrossRefPubMedGoogle Scholar
  7. 7.
    Gershon AA, Mervish N, LaRussa P, Steinberg S, Lo SH, Hodes D et al (1997) Varicella-zoster virus infection in children with underlying human immunodeficiency virus infection. J Infect 176:1496–1500CrossRefGoogle Scholar
  8. 8.
    Mahalingam R, Wellish M, Cohrs R, Debrus S, Piette J, Rentier B et al (1996) Expression of protein encoded by varicella-zoster virus open reading frame 63 in latently infected human ganglionic neurons. Proc Natl Acad Sci U S A 93:2122–2124CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Kennedy PG, Rovnak J, Badani H, Cohrs RJ (2015) A comparison of herpes simplex virus type 1 and varicella-zoster virus latency and reactivation. J Gen Virol 96:1581–1602CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Arvin AM, Moffat JF, Redman R (1996) Varicella-zoster virus: aspects of pathogenesis and host response to natural infection and varicella vaccine. Adv Virus Res 46:263–309CrossRefPubMedGoogle Scholar
  11. 11.
    Schneweis KE, Krentler C, Wolff MH (1985) Durchseuchung mit dem Varicella-Zoster-Virus und serologische Feststellung der Erstimmunität. Dtsch Med Wochenschr 110:453–457CrossRefPubMedGoogle Scholar
  12. 12.
    Sauerbrei A, Wutzler P (2004) Varicella-Zoster-Virus-Infektionen: Aktuelle Prophylaxe und Therapie, 1st edn. Uni-Med, Bremen, pp 44–53Google Scholar
  13. 13.
    Wutzler P, Knuf M, Liese J (2008) Varicella: efficacy of two-dose vaccination in childhood. Dtsch Arztebl Int 105:567–572PubMedPubMedCentralGoogle Scholar
  14. 14.
    Arvin AM (1999) Management of varicella-zoster virus infections in children. Adv Exp Med Biol 458:167–174CrossRefPubMedGoogle Scholar
  15. 15.
    Sauerbrei A (2007) Varicella-zoster virus infections during pregnancy. In: Mushahwar K (ed) Congenital and other related infectious diseases of the newborn. Perspectives in Medical Virology, vol 13. Elsevier, Amsterdam, pp 51–73CrossRefGoogle Scholar
  16. 16.
    Quinlivan M, Breuer J (2006) Molecular studies of Varicella zoster virus. Rev Med Virol 16:225–250CrossRefPubMedGoogle Scholar
  17. 17.
    Vázquez M, Shapiro ED (2005) Varicella vaccine and infection with varicella-zoster virus. N Engl J Med 352:439–440CrossRefPubMedGoogle Scholar
  18. 18.
    Ultsch B, Köster I, Reinhold T, Siedler A, Krause G, Icks A et al (2013) Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany. Eur J Health Econ 14:1015–1026CrossRefPubMedGoogle Scholar
  19. 19.
    Siedler A, Hecht J, Rieck T, Tolksdorf K, Hengel H (2013) Die Varizellenimpfung in Deutschland. Eine Zwischenbilanz mit Blick auf die Masern-Mumps-Röteln (MMR-)Impfung. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 56:1313–1320CrossRefPubMedGoogle Scholar
  20. 20.
    Gross G (1997) Zoster—Manifestationsformen an der Haut, Komplikationen und Therapie. Dtsch Med Wochenschr 122:132–139CrossRefPubMedGoogle Scholar
  21. 21.
    Wutzler P, Meister W (1997) Herpes zoster—Symptomatologie, demographische Daten und prognostische Faktoren. Dtsch Ärztebl 94:A1129–A1133Google Scholar
  22. 22.
    Sauerbrei A (2014) Windpocken (Varizellen). In: S2k-Leitlinie: Labordiagnostik schwangerschaftsrelevanter Virusinfektionen. Springer, Berlin, Heidelberg, pp 95–110Google Scholar
  23. 23.
    Sauerbrei A, Eichhorn U, Schacke M, Wutzler P (1999) Laboratory diagnosis of herpes zoster. J Clin Virol 14:31–36CrossRefPubMedGoogle Scholar
  24. 24.
    Sauerbrei A, Wutzler P (2002) Laboratory diagnosis of central nervous system infections caused by herpesviruses. J Clin Virol 25(Suppl 1):S45–S51CrossRefPubMedGoogle Scholar
  25. 25.
    Sauerbrei A, Uebe B, Wutzler P (2003) Molecular diagnosis of zoster post varicella vaccination. J Clin Virol 27:190–199CrossRefPubMedGoogle Scholar
  26. 26.
    Sauerbrei A, Stefanski J, Philipps A, Krumbholz A, Zell R, Wutzler P (2011) Monitoring prevalence of varicella-zoster virus clades in Germany. Med Microbiol Immunol 200:99–107CrossRefPubMedGoogle Scholar
  27. 27.
    Sauerbrei A, Wutzler P (2004) Labordiagnostik der Varizellen. Kinderärztl Prax, Sonderheft Impfen, pp 18–21Google Scholar
  28. 28.
    Sauerbrei A, Färber I, Brandstädt A, Schacke M, Wutzler P (2004) Immunofluorescence test for sensitive detection of varicella-zoster virus-specific IgG: an alternative to fluorescent antibody to membrane antigen test. J Virol Methods 119:25–30CrossRefPubMedGoogle Scholar
  29. 29.
    Sauerbrei A, Wutzler P (2006) Serological detection of varicella-zoster virus-specific immunoglobulin G by an enzyme-linked immunosorbent assay using glycoprotein antigen. J Clin Microbiol 44:3094–3097CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Kneitz RH, Schubert J, Tollmann F, Zens W, Hedman K, Weissbrich B (2004) A new method for determination of varicella-zoster virus immunoglobulin G avidity in serum and cerebrospinal fluid. BMC Infect Dis 4:33CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Fillet AM, Visse B, Caumes E, Dumont B, Gentilini M, Huraux JM (1995) Foscarnet-resistant multidermatomal zoster in a patient with AIDS. Clin Infect Dis 21:1348–1349CrossRefPubMedGoogle Scholar
  32. 32.
    Saint-Léger E, Caumes E, Breton G, Douard D, Saiag P, Huraux JM et al (2001) Clinical and virologic characterization of acyclovir-resistant varicella-zoster viruses isolated from 11 patients with acquired immunodeficiency syndrome. Clin Infect Dis 33:2061–2067CrossRefPubMedGoogle Scholar
  33. 33.
    Sauerbrei A, Taut J, Zell R, Wutzler P (2011) Resistance testing of clinical varicella-zoster virus strains. Antiviral Res 90:242–247CrossRefPubMedGoogle Scholar
  34. 34.
    Piret J, Boivin G (2011) Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemother 55:459–472CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Balfour HH Jr, Benson C, Braun J, Cassens B, Erice A, Friedman-Kien A et al (1994) Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections. J Acquir Immune Defic Syndr 7:254–260PubMedGoogle Scholar
  36. 36.
    Sauerbrei A (2014) Diagnostik und antivirale Therapie von Herpes-simplex-Virus-Infektionen. Der Mikrobiol 24:151–158Google Scholar
  37. 37.
    Safrin S, Berger TG, Gilson I, Wolfe PR, Wofsy CB, Mills J et al (1991) Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection. Ann Intern Med 115:19–21CrossRefPubMedGoogle Scholar
  38. 38.
    Morfin F, Thouvenot D (2003) Herpes simplex virus resistance to antiviral drugs. J Clin Virol 26:29–37CrossRefPubMedGoogle Scholar
  39. 39.
    Safrin S, Crumpacker C, Chatis P, Davis R, Hafner R, Rush J et al (1991) A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med 325:551–555CrossRefPubMedGoogle Scholar
  40. 40.
    Schubert A, Gentner E, Bohn K, Schwarz M, Mertens T, Sauerbrei A (2014) Single nucleotide polymorphisms of thymidine kinase and DNA polymerase genes in clinical herpes simplex virus type 1 isolates associated with different resistance phenotypes. Antiviral Res 107:16–22CrossRefPubMedGoogle Scholar
  41. 41.
    Brunnemann AK, Bohn-Wippert K, Zell R, Henke A, Walther M, Braum O et al (2015) Drug resistance of clinical varicella-zoster virus strains confirmed by recombinant thymidine kinase expression and by targeted resistance mutagenesis of a cloned wild-type isolate. Antimicrob Agents Chemother 59:2726–2734CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Oh SH, Choi EH, Shin SH, Kim YK, Chang JK, Choi KM et al (2014) Varicella and varicella vaccination in South Korea. Clin Vaccine Immunol 21:762–768CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Gershon AA (1997) Live attenuated varicella vaccine. Int J Infect Dis 1:130–134CrossRefGoogle Scholar
  44. 44.
    Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T, Isomura S (1974) Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 2:1288–1290CrossRefPubMedGoogle Scholar
  45. 45.
    Arvin A, Gershon A (2006) Control of varicella: why is a two-dose schedule necessary? Pediatr Infect Dis J 25:475–476CrossRefPubMedGoogle Scholar
  46. 46.
    Luthy KE, Tiedeman ME, Beckstrand RL, Mills DA (2006) Safety of live-virus vaccines for children with immune deficiency. J Am Acad Nurse Pract 18:494–503CrossRefPubMedGoogle Scholar
  47. 47.
    Damm O, Ultsch B, Horn J, Mikolajczyk RT, Greiner W, Wichmann O (2015) Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries. BMC Public Health 15:533CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Liese JG, Cohen C, Rack A, Pirzer K, Eber S, Blum M et al (2013) The effectiveness of varicella vaccination in children in Germany: a case–control study. Pediatr Infect Dis J 32:998–1004CrossRefPubMedGoogle Scholar
  49. 49.
    Gershon AA (2001) The current status of live attenuated varicella vaccine. Arch Virol Suppl 17:1–6PubMedGoogle Scholar
  50. 50.
    Chaves SS, Lopez AS, Watson TL, Civen R, Watson B, Mascola L et al (2011) Varicella in infants after implementation of the US varicella vaccination program. Pediatrics 128:1071–1077CrossRefPubMedGoogle Scholar
  51. 51.
    Seward JF, Watson BM, Peterson CL, Mascola L, Pelosi JW, Zhang JX et al (2002) Varicella disease after introduction of varicella vaccine in the United States, 1995–2000. JAMA 287:606–611CrossRefPubMedGoogle Scholar
  52. 52.
    Ampofo K, Saiman L, LaRussa P, Steinberg S, Annunziato P, Gershon A (2002) Persistence of immunity to live attenuated varicella vaccine in healthy adults. Clin Infect Dis 34:774–779CrossRefPubMedGoogle Scholar
  53. 53.
    Kuter B, Matthews H, Shinefield H, Black S, Dennehy P, Watson B et al (2004) Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J 23:132–137CrossRefPubMedGoogle Scholar
  54. 54.
    Marin M, Meissner HC, Seward JF (2008) Varicella prevention in the United States: a review of successes and challenges. Pediatrics 122:e744–e751CrossRefPubMedGoogle Scholar
  55. 55.
    Marin M, Nguyen HQ, Keen J, Jumaan AO, Mellen PM, Hayes EB et al (2005) Importance of catch-up vaccination: experience from a varicella outbreak, Maine, 2002–2003. Pediatrics 115:900–905CrossRefPubMedGoogle Scholar
  56. 56.
    Lopez AS, Cardemil C, Pabst LJ, Cullen KA, Leung J, Bialek SR et al (2014) Two-dose varicella vaccination coverage among children aged 7 years—six sentinel sites, United States, 2006–2012. MMWR Morb Mortal Wkly Rep 63:174–177PubMedGoogle Scholar
  57. 57.
    Leung J, Harpaz R, Molinari NA, Jumaan A, Zhou F (2011) Herpes zoster incidence among insured persons in the United States, 1993–2006: evaluation of impact of varicella vaccination. Clin Infect Dis 52:332–340CrossRefPubMedGoogle Scholar
  58. 58.
    Sauerbrei A (2014) Herpes zoster im Kindes- und Jugendalter. Monatsschr Kinderheilkd 162:1135–1144CrossRefGoogle Scholar
  59. 59.
    Weinmann S, Chun C, Schmid DS, Roberts M, Vandermeer M, Riedlinger K et al (2013) Incidence and clinical characteristics of herpes zoster among children in the varicella vaccine era, 2005–2009. J Infect Dis 208:1859–1868CrossRefPubMedGoogle Scholar
  60. 60.
    Uebe B, Sauerbrei A, Burdach S, Horneff G (2002) Herpes zoster by reactivated vaccine varicella zoster virus in a healthy child. Eur J Pediatr 161:442–444CrossRefPubMedGoogle Scholar
  61. 61.
    Robert Koch-Institut (2004) Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut (Stand: Juli 2004). Epidemiol Bull 30:235–250Google Scholar
  62. 62.
    Streng A, Grote V, Carr D, Hagemann C, Liese JG (2013) Varicella routine vaccination and the effects on varicella epidemiology—results from the Bavarian Varicella Surveillance Project (BaVariPro), 2006–2011. BMC Infect Dis 13:303CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Robert Koch-Institut (2009) Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut (Stand: Juli 2009). Epidemiol Bull 30:279–298Google Scholar
  64. 64.
    Robert Koch-Institut (2011) Zur Kombinationsimpfung gegen Masern, Mumps, Röteln und Varizellen (MMRV). Epidemiol Bull 38:352–353Google Scholar
  65. 65.
    Robert Koch-Institut (2015) Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut (Stand: August 2015). Epidemiol Bull 34:327–362Google Scholar
  66. 66.
    Sauerbrei A, Wutzler P (2007) Varicella-Zoster-Virus-Infektionen: Aktuelle Prophylaxe und Therapie, 2nd edn. Uni-Med, Bremen, pp 70–87Google Scholar
  67. 67.
    Galea SA, Sweet A, Beninger P, Steinberg SP, LaRussa PS, Gershon AA et al (2008) The safety profile of varicella vaccine: a 10-year review. J Infect Dis 197:S165–S169CrossRefPubMedGoogle Scholar
  68. 68.
    Robert Koch-Institut (2005) Neuerungen in den aktuellen Impfempfehlungen der STIKO. Epidemiol Bull 31:273–276Google Scholar
  69. 69.
    Sauerbrei A (2011) Preventing congenital varicella syndrome with immunization. CMAJ 183:E169–E170CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Arvin A (2005) Aging, immunity, and the varicella-zoster virus. N Engl J Med 352:2266–2267CrossRefPubMedGoogle Scholar
  71. 71.
    Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD et al (2005) A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352:2271–2284CrossRefPubMedGoogle Scholar
  72. 72.
    Vesikari T, Hardt R, Rümke HC, Icardi G, Montero J, Thomas S et al (2013) Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥70 years: a randomized study of a single dose vs. two different two-dose schedules. Hum Vaccin Immunother 9:858–564CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Leroux-Roels I, Leroux-Roels G, Clement F, Vandepapelière P, Vassilev V, Ledent E et al (2012) A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein E subunit vaccine candidate in young and older adults. J Infect Dis 206:1280–1290CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  1. 1.Institute of Virology and Antiviral Therapy, German Consulting Laboratory for HSV and VZV, Jena University HospitalFriedrich-Schiller UniversityJenaGermany

Personalised recommendations